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Background/Aims: The Compliance Questionnaire-Rheumatology (CQR) is a validated scale to evaluate patient
compliance for anti-rheumatic medications. We developed a Korean version of the CQR (KCQR) and confirmed its
reliability and validity.
Methods: We prepared the KCQR by translating and back-translating the original CQR with modifications to
adapt it to Korean culture. Fifty Korean patients with rheumatoid arthritis (RA) were enrolled in this study. The
test-retest reliability of the KCQR was evaluated at a 2-week interval using the intraclass correlation coefficient
(ICC). The validity of the KCQR was assessed by identifying associations between KCQR scores and patient
compliance, measured using pharmacy refill data.
Results: The reliability of the KCQR was adequate, with an ICC of 0.71 for test-retest reliability. With respect to
validity, the summed score of the weighted KCQR showed a significant correlation with pharmacy refill data (r
2 =
0.57) on multiple regression analysis.
Conclusions: Our results indicate that the KCQR is a reliable, valid instrument to evaluate compliance of Korean
patients for RA medications. (Korean J Intern Med 2011;26:28-33)
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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic inflammatory
disease, causing chronic inflammation of the joints and
various organs. Despite the recent development of differ-
ent agents, the long-term use of anti-rheumatic drugs is
still an essential part of the management strategies for
patients with RA [1,2]. Medication compliance is of partic-
ular importance in patients who suffer from chronic dis-
eases such as RA, because these patients are easily dis-
couraged by the prospect of lifetime treatment with
imperfect anti-rheumatic drugs [3]. It has been reported
that greater compliance leads directly to enhanced clinical
effects [4,5]. Noncompliance causes several critical prob-
lems in the management of these patients, including
unnecessary health costs, changes in treatment, morbidi-
ty, and potential mortality [6]. Thus, measuring and pre-
dicting the compliance of a particular patient is a useful
tool for optimal patient management.
Medication compliance can be quantified in several
ways [7], including direct and indirect measures of inges-
tion, clinical measures, and patient self-reporting [8].
Direct measurement of ingestion involves quantifying the
concentrations of substances in body fluids. Indirect mea-
surements include monitoring pharmacy refills, tablet
counts, and the use of electronic devices and question-
naires. Clinical measures require clinical judgment and
using therapeutic outcome to infer the degree of compli-Lee JY, et al. Korean compliance questionnaire rheumatology    29
ance. Obviously, patient self-reporting depends solely on
the patient.
Using a validated compliance questionnaire has several
advantages over the other methods. It can be done easily
without requiring an invasive procedure, it is inexpensive,
and it provides relatively accurate measures of true com-
pliance and can encourage real-life compliance.
Furthermore, it can predict a particular patient’s compli-
ance, not just measure compliance results [8-10]. There
are at least two English-language compliance question-
naires for rheumatologic diseases [11,12]. However, there
is no validated compliance questionnaire written in
Korean in widespread use. Thus, we developed a Korean
version of a compliance questionnaire, based on the
Compliance Questionnaire-Rheumatology (CQR), a vali-
dated scale for comparing self-reported compliance and
electronic medical device findings [12,13].
METHODS
Patients
Fifty Korean patients with RA who agreed to take part
in the study were enrolled from the Rheumatologic Clinic
of Seoul National University Hospital. All patients met the
classification criteria for RA of the American College of
Rheumatology [14]. 
The Institutional Review Board of Seoul National
University Hospital approved this study. Appropriate
informed consent was obtained.
Translation of the CQR
The CQR was translated into Korean by three transla-
tors, and an initial draft KCQR was prepared by one of the
authors (SYL), and was then translated back into English
by the other three authors (JYL, HJH, EBL). During the
translation/back-translation procedure, one question was
modified. Because medication organizers are not popular
in Korea, the sentence “I use a dose organizer for my med-
ications” was changed to “I use a special way so that I
don’t forget to take my anti-rheumatic medicines, like a
pocketbook, calendar, or alarm clock”. A four-point Likert
scale was adopted with the anchors “don’t agree at all”
(score = 1), “don’t agree” (score = 2), “agree” (score = 3),
and “agree very much” (score = 4). To check the appropri-
ateness of the translated questionnaire, we conducted a
field test in seven patients. The results of the field test led
to the revision of four items on the questionnaire to
enhance patient comprehension. One native American
who is bilingual in English and Korean reviewed the final
result. The final version of the KCQR is summarized in
Figure 1.
Reliability
Reliability was tested using the test-retest method per-
formed with a 2-week interval between the two processes.
The first test was done when the patient visited the clinic.
The questionnaire was mailed to their homes 1 week later.
Two weeks after they had taken the first test, the patients
were telephoned and asked to open and complete the
questionnaire. Thirty-six patients completed the retest
and returned completed questionnaires.
Validity
The validity of the KCQR was assessed by comparing
the KCQR scores and compliance as measured by phar-
macy refill data (refill compliance). The following medica-
tions were included for validity analysis: systemic non-
steroidal anti-inflammatory drugs (NSAIDs), disease-
modifying anti-rheumatic drugs (DMARDs), and antiul-
cer medications. On-demand medications, topical prepa-
rations, and medications prescribed transiently were
excluded from the pharmacy refill analysis. Pharmacy
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refill data for 41 patients who took medication for more
than 6 months were obtained.
In Korea, the National Health Insurance Review Agency
(HIRA) governs health insurance for all Koreans. A doctor
diagnoses a patient and issues a prescription. With the
prescription in hand, the patient visits a drugstore to get
the medicine. In this study, pharmacy refill data were
obtained in two steps. After obtaining prescription refill
data from Seoul National University Hospital, the final
pharmacy refill data were completed with dispensation
records from drugstores, which were obtained from
HIRA. Refill compliance was calculated as (total dose of
medication prescribed and dispensed)/(total number of
prescribed doses) ×100%.
Statistical analyses
The KCQR score was calculated as the sum of 19 scored
items. Some of the items in the CQR received a negative
score if the patient indicated less compliance. These items
were recoded (score 1→4, 2→3, 3→2, 4→1) to obtain a
useful total score, where high scores are related to higher
compliance. Test-retest reliability was measured by calcu-
lating the intraclass correlation coefficient (ICC), a mea-
sure of concordance that corrects for systemic errors [15].
To evaluate validity, the KCQR scores and refill compli-
ance were analyzed using Pearson correlation coefficients.
Multiple regression analyses were used to obtain the
weights that increased the correlation between KCQR
score and refill compliance, as previously reported [13]. All
analyses were performed using the SPSS version 12.0
(SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
The baseline characteristics of the 41 patients who
entered into the final analysis are summarized in Table 1.
The mean (± standard deviation) age of the patients was
58.0 (± 12.4) years. There were 31 females and ten males.
Twenty-three patients (56.1%) had a disease duration
exceeding 5 years, while five patients had a disease dura-
tion less than 1 year. The duration of medication was simi-
lar to the disease duration.
Reliability
Of the 50 patients who completed the first test, 36
patients (72.0%) returned the mailed retest questionnaire.
The average score (± SD) was 61.39 (± 5.97) on the first
measurement and 61.50 (± 6.84) 2 weeks later. The test-
retest reliability gave an intraclass correlation coefficient
of 0.71 (95% confidence interval [CI], 0.50 to 0.84) for the
KCQR score.
Table 1. Baseline characteristics of the patients in the
validity analysis (n = 41)
Patient characteristics No.
Age, yr (mean ± SD) 58.0 ± 12.4
Gender  
Male 10
Female 31
Duration of disease, yr  
≤ 1  1
> 1 - 3  8
> 3 - 5 9
> 5   23
Duration of mediation use, yr  
≤ 1   1
> 1 - 3  8
> 3 - 5  10
> 5  22
Medication use  
Steroid 7
Non-Steroidal anti-Inflammatory Drugs
Meloxicam 12
Celecoxib 8
Naproxen 7
Others 8
Disease-modifying anti-rheumatic drugs
Bucillamine 7
Hydroxychloroquine 23
Leflunomide 9
Methotrexate 31
Sulfasalazine 14
Calcium 14
Antiulcer medication 29Lee JY, et al. Korean compliance questionnaire rheumatology    31
Validity
Compliance as measured using the record of pharmacy
refills was 89.4 ± 14.5%. The total KCQR score, which was
the sum of the unweighted individual items, showed a low
correlation with refill compliance (r
2 = 0.13, p = 0.020)
(Fig. 2). However, when individual items were weighted
with the values inferred from the multiple regression
analysis (Table 2), the KCQR showed significant correla-
tion with refill compliance (r
2 = 0.57) (Fig. 3), indicating
that weighting is an essential step in interpreting the
KCQR.
DISCUSSION
In this study, we developed a Korean version of the
CQR. Our KCQR showed adequate reliability (ICC = 0.71)
for clinical application. The validity of the instrument,
which was calculated from refill compliance, was also ade-
quate for clinical use (r
2= 0.57).
The study of the original CQR measured compliance in
patients with RA, polymyalgia rheumatica, and gout [13].
However, we restricted our study to patients with RA
because the immediate clinical effects of non-compliance
in RA and gout are different. Non-compliance in RA can
lead to brief aggravation of arthralgia, while there is no
such immediate effect in gout. Polymyalgia rheumatica is
very rare in Koreans.
Pharmacy refill data were used to infer the true value of
compliance in this study. A direct chemical measurement
method was excluded because measurement methods
have not been established for some medications. Of the
indirect measurement methods, we could not accept
tablet counts or electronic monitoring methods because
they affect real-life compliance. There are many reports
that using an electronic monitoring device can increase
compliance [16-22]. Clinical compliance was inadequate
because most of the enrolled patients were those of one of
the authors (EBL). Some authors have suggested that self
reporting is a useful measurement technique, if the client
is interviewed at home [23-25]. However, this still has the
inherent limitation that it is purely subjective. Refill com-
Table 2. Discriminated weights for KCQR prediction
function
KCQR items Weight KCQR items Weight
Constant 50.192 10 -6.629
1 -5.053 11 -0.639
2 -1.079 12 3.239
3 -3.972 13 2.582
4 0.565 14 -3.115
5 9.076 15 -5.625
6 -6.551 16 4.989
7 3.382 17 17.372
8 0.065 18 2.074
9 1.707 19 2.297
KCQR, Korean version of the Compliance Questionnaire-
Rheumatology.
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Figure 2. Correlation between refill compliance and the Korean
version of the Compliance Questionnaire-Rheumatology (KCQR)
score (r
2 = 0.13, p = 0.02). Refill compliance was obtained from
pharmacy refill data for 41 patients who took medication for more
than 6 months. 
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Figure 3. Correlation between refill compliance and the weighted
Korean version of the Compliance Questionnaire-Rheumatology
(KCQR) score (r
2 = 0.57, p < 0.001). Refill compliance was
obtained from pharmacy refill data for 41 patients who took med-
ication for more than 6 months. Multiple regression analyses were
used to obtain the weights that increased the correlation between
the KCQR score and refill compliance.  32 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
pliance based on pharmacy refill data is a method that
best reflects real-life compliance. The unique Korean
health insurance system, administered by one nationwide
government agency, enabled us to measure pharmacy
refill data accurately. Because all drugstores in Korea are
reimbursed by one agency, it is possible to trace all dis-
pensation data from all drugstores. Thus, we used refill
compliance as a surrogate for true compliance. The com-
pliance of Korean RA patients as measured by pharmacy
refill data in this study was 89.4 ± 14.5%, which is compa-
rable to other studies [13], suggesting that the estimation
of true compliance in our study was adequate.
The test-retest reliability yielded an intraclass correla-
tion coefficient of 0.71 for the KCQR score, which is com-
parable to the original CQR study (0.73) [13]. The simple
sum of the KCQR correlated weakly with pharmacy refill
compliance, whereas the weighted sum of the KCQR cor-
related adequately. Two highly weighted questions were
#16 (I use a dose organizer for my medications) and #17
(What the doctor tells me, I remember). This study
changed the former to “I use a special way so that I don’t
forget to take my anti-rheumatic medicines, like a pocket-
book, calendar, or alarm clock”. Question #5 (My medi-
cines are always stored in the same place, and that’s why I
don’t forget them) also addresses the concept that patients
may have established a special way to remember to take
their anti-rheumatic medications and was also weighted
heavily. The answers to these questions, especially ques-
tions #16 and #5, proved valuable when determining the
compliance in RA patients. Doctors and pharmacists
should advise patients to keep their medicines in the same
place each day and develop a special way to remember to
take them.
The KCQR has many advantages over other compli-
ance-measuring methods. It is simple and can be adminis-
tered easily without the help of an investigator. The ques-
tionnaire can be completed within 10 minutes. As we
demonstrated, it has good reliability and validity. A dis-
tinct merit of this questionnaire is that it can be used to
predict the level of compliance before medication is start-
ed. This is very useful for devising treatment plans for
individual patients. Additionally, most clinical trials of
new anti-rheumatic drugs require long periods of partic-
ipation by patients, as most rheumatic diseases require
long-term treatment. In this respect, the KCQR may be
used to screen participants for their potential participation
in such studies.
This study analyzed 41 of the 50 patients enrolled.
Despite a suggestion that 30 patients are enough for cul-
tural adaptation studies [26], more patients may give
more reliable results. This limitation needs to be consid-
ered when interpreting the results.
In conclusion, we developed a Korean version of a com-
pliance questionnaire for rheumatoid arthritis. It showed
adequate reliability and validity for clinical application
compared to international studies. However, more studies
are warranted to develop an instrument specifically tai-
lored to Korean patients with RA.
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